Get Started
Breast Cancer Curricula
Step 1

The Advanced Certificate Program in
Breast Cancer Management III
  1. Course List
faculty image
Harold J. Burstein, MD, PhD
  • Associate Professor of Medicine
  • Dana-Farber Cancer Institute
  • Harvard Medical School
  • Boston, Massachusetts
  • Director/Peer Reviewer
    faculty image
    Christine M. Pellegrino, MD
  • Assistant Clinical Professor
  • Department of Medicine
  • Albert Einstein College of Medicine of Yeshiva University
  • Bronx, New York
  • Projects In Knowledge is pleased to present The Advanced Certificate Program: Breast Cancer Management comprised of Curricula I and II.
    Curriculum I courses present a basic overview of management strategies for optimal personalized care of breast cancer patients. Curriculum II presents more advanced courses that build on new scientific developments and the topics covered in Curriculum I. Curriculum III presented by Albert Einstein College of Medicine and Projects In Knowledge provides updates on prognostic tools, newer targeted treatments, and safety of hormonal therapies and chemotherapy. It also includes case studies illustrating management decisions and treatment options for patients with refractory HER2-positive or hormone-receptor–positive metastatic breast cancer.
    Featuring the very latest state-of-the-science information about breast cancer diagnosis, breast cancer treatment, and breast cancer disease management, this free online curriculum offers CME, CE, and CPE credit to oncologists and other clinicians who care for patients with breast cancer.
    The curriculum courses are updated continuously throughout the year. The Advanced Certificate Program: Breast Cancer Management is building a community of experts to help you provide your patients with the best treatment outcome possible.
  • Assess new data on molecular diagnostic tests in breast cancer (including genetic tests) that determine patients who may benefit from specific therapies to improve associated treatment decisions.
  • Analyze and contrast the MOAs, efficacy, safety, dosing, treatment strategies, clinical considerations, and overall survival rates of breast cancer patients on current and emerging chemotherapies, hormone therapies, targeted therapies, and PARP inhibitors.
  • Differentiate among side effects associated with chemotherapeutic agents, hormone therapies (including bone health), targeted therapies, and PARP inhibitors, and risk stratification and side effect management strategies to improve adherence/outcomes.
  • Assess the importance and challenges in advocating lifestyle changes, treatment adherence, the consequences of non-adherence, and methods for improving adherence.
  • Formulate strategies for a multidisciplinary approach to the management of breast cancer.
    • Early-stage breast cancer management
      • Chemotherapy
      • Endocrine/hormone therapy
      • Targeted therapy
      • Bisphosphonates
      • Aspirin
    • Metastatic breast cancer management
      • Chemotherapy
      • Hormone therapy
      • Targeted therapies
        - Anti-HER2 agents
        - Antiangiogenic agents
        - PARP inhibitors
      • Novel therapy TDM1
      • Bone metastasis management
    • Neoadjuvant therapy
      • Translational therapy
    • Hereditary breast cancer
    • Adjuvant treatment for premenopausal and postmenopausal women
    • Hormone-receptor-positive breast cancer
    • Primary endocrine therapy
    • Estrogen-receptor-positive breast cancer
    • Systemic therapies for first-, second-, and third-line treatment of metastatic breast cancer
    • Biomolecular predictors
    • Adjuvant systemic therapy in early-stage breast cancer
    • Estrogen-responsive genes in metastases to the bone
    • Cancer risk assessment with biomarkers
    • Postoperative treatment with targeted therapies for patients with HER2+ & HER2- disease
    • Dose-dense adjuvant therapy
    • Hormonal therapy for advanced breast cancer
    • Neoadjuvant systemic therapy
    • Molecular screening for breast cancer
    • 21-gene recurrence score prognostic assay
    • Small (subcentimeter) HER2+ breast cancer
    • Triple-negative breast cancer
    • Endocrine-sensitive, HER2- breast cancer in postmenopausal women
    • Impact of aromatase inhibitors on bone health
    • Promoting adherence
    • Treatment of refractory HER2+ disease
    • Treatment of refractory HR+ disease

    Target Audience

    This series of activities is designed for medical oncologists, as well as nurses and pharmacists, who manage and treat patients with breast cancer.


    Activity Goal

    The goal of these CME/CE activities is to examine current and emerging strategies for diagnosing, treating, and managing patients with breast cancer.